Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | The rationale behind the E3311 trial exploring de-escalated radiation therapy for HPV+ OPV

Ari Rosenberg, MD, University of Chicago, Chicago, IL, talks on the rationale behind the Phase II E3311 (NCT01898494) study investigating patients with intermediate risk HPV+ oropharynx cancer (OPC) who underwent transoral surgery (TOS) followed by pathology-guided or adapted, deintensified adjuvant treatment. Full-dose chemoradiation 70 Gy with concurrent cisplatin is associated with several acute and severe toxicities. HPV+ OPC is associated with good prognosis in terms of overall-survival (OS) and progression-free survival (PFS), however determining the feasibility of de-escalated treatment for selected patients could help improve patient quality of life. The aim of E3311 was to select patients for deintensified radiation to help patients avoid unnecessary toxicities and ultimately increase quality of life. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.